FDA Approved: RIABNI — Supplemental Application (Amgen, Inc)

View source ↗

Summary

FDA approved a supplemental application for RIABNI (rituximab-arrx) from Amgen. The action updates RIABNI’s labeling to reflect its approved indications consist…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Follicular Lymphoma
• Granulomatosis with Polyangiitis
• Microscopic Polyangiitis
• Non-hodgkin Lymphoma
• Rheumatoid Arthritis
• Small Lymphocytic Lymphoma

Drugs mentioned

• RIABNI (RITUXIMAB-ARRX)

Snippet

SUPPL AP for RIABNI (RITUXIMAB-ARRX)